Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 3Breast Neoplasms 3Stomatitis 2Neoplasms 2Mucositis 2Vulvodynia 1Urologic Neoplasms 1Urologic Diseases 1Urolithiasis 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Pain, Postoperative 1Pain 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Mobility Limitation 1MRSA Colonization 1Lymphoma 1Leukemia 1Ilues 1Hydronephrosis 1Hematologic Diseases 1Head and Neck Neoplasms 1Dyspareunia 1Disease 1

Interventions

Morphine 11Oxycodone 8Fentanyl 6nabiximols 5Methadone 4Hydromorphone 4Acetaminophen 3Transcutaneous Electric Nerve Stimulation 2Tapentadol 2Naloxone 2Lidocaine 2Buprenorphine 2Acupuncture Therapy 2tanezumab 1resiniferatoxin 1oxycodone naloxone combination 1fulranumab 1cannabichromene 1alvimopan 1Water 1Ultracet 1Transcranial Direct Current Stimulation 1Tramadol 1Therapeutic Touch 1Telemedicine 1Tablets 1Surveys and Questionnaires 1Sugars 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cancer Pain × Water × Clear all
NCT01384877 2019-07-12

Subcutaneous Lidocaine For Cancer-Related Pain

British Columbia Cancer Agency

Phase 2/3 Completed
33 enrolled 16 charts

Cancer Pain, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡